SAN DIEGO & MINEOLA, N.Y.--(BUSINESS WIRE)--Sequenom, Inc. (NASDAQ:SQNM) and Lenetix Medical Screening Laboratory, Inc., a provider of rapid genetic screening and diagnostic testing for clinicians worldwide, today announced that Lenetix has submitted a clinical package to the New York State Department of Health to support its application for a clinical laboratory permit to perform a non-invasive prenatal Rhesus D (RhD) incompatibility test, the first non-invasive prenatal test based on Sequenom’s Fetal Nucleic Acid Technology. The prenatal RhD incompatibility test will be marketed as a “home brew” and performed on a real-time PCR (RT-PCR) platform. In preparation for New York State approval, Lenetix is preparing marketing and scientific materials to commercialize the RhD incompatibility test throughout the United States.
